Acclinate Strengthens Commitment to Diversity in Clinical Research
Acclinate, a noted leader in enhancing trust within clinical research, is breaking new ground in engaging Hispanic and Indigenous communities. The company is making significant strides by introducing a groundbreaking initiative to mobilize participants in clinical studies within a concise 30-day timeframe. Utilizing culturally relevant strategies in tandem with their advanced AI/ML technology, Acclinate is working to reduce recruitment times and address the long-standing issues of representation within clinical trials.
Over the past several years, Acclinate has been meticulously refining its trust-based model, which has proven effective as its community, NOWINCLUDED, has expanded to an impressive 200,000 members. By using their proprietary Participation Probability Index (PPI), which leverages a wealth of sentiment data, Acclinate is offering pharmaceutical companies a reliable method to enhance enrollment among underrepresented groups. This initiative not only aims to meet diversity targets but also ensures that engagement is conducted on time and within budget.
"For too long, the industry has viewed clinical trial representation and recruitment speed as opposing forces. At Acclinate, we demonstrate that trust can significantly accelerate scientific progress," shares Del Smith, the CEO of Acclinate.
The Urgent Need for Diverse Clinical Data
Current statistics reveal that a mere 6% of clinical trials that facilitate drug approvals in the United States accurately reflect the nation's racial and ethnic diversity. A recent study indicates a troubling shortfall in the representation of Black or African American individuals in oncology trials, where their national population percentage is 13.7%, but their trial participation hovers around just 1.7%. Hispanic or Latino groups show similarly alarming trends at only 7.1% representation compared to 20.0% of the population.
Additionally, Indigenous populations consistently make up less than 1.0% of clinical trial participants. This lack of diverse data raises concerns regarding the safety and efficacy of treatments we develop, underscoring the importance of inclusive research practices.
e-DICT: Enhancing Predictive Engagement
To address the disparity in clinical trial participation, Acclinate has advanced its unique e-DICT™ platform, which allows for the collection and analysis of engagement data across various community channels. This includes both online platforms and relatable offline activities that help gauge community sentiment and trust effectively. This real-time data provides valuable insights into the willingness of diverse demographic groups to participate.
Acclinate’s Head of Commercial, Kyle Ashe, states, "By refining our predictive capabilities over the past five years, we can eliminate the 'cold start' problem in community engagement. We generate actionable insights long before a study opens, transforming recruitment efforts from reactive to proactive."
Building Community-Driven Partnerships
The company’s expansion into Hispanic and Indigenous communities reflects a purposeful step towards mobilizing one million lives for enhanced health outcomes. Meagan Holland, Acclinate's Director of Strategic Partnerships, emphasizes, "We have strategically built a network of patient organizations and community ambassadors who engage daily with these populations. Our goal is to interweave their insights and experiences with our platform’s capabilities to promote trust and participation."
Acclinate is not just about recruitment; it is about ensuring that clinical research is a collaborative journey where communities are active participants rather than passive subjects.
Alignment with Regulatory Expectations
This community-centered approach resonates with recent FDA guidance aimed at increasing participation in clinical trials. It encourages sponsors to foster enduring relationships rather than viewing recruitment as a transaction. This strategy empowers Acclinate to help sponsors comply with regulatory demands while innovating how they approach patient recruitment and retention for better outcomes.
About Acclinate
Acclinate is an acclaimed health equity organization focused on improving representation in clinical research. Through initiatives like NOWINCLUDED and the e-DICT™ platform, the company fosters trust and enhances the participation of diverse populations, ensuring studies are designed to meet the needs of real communities. Their commitment lies in cultural relevance, transparency, and building enduring partnerships with the communities they serve.
Media Contact
Lauren Clements
Head of Marketing, Acclinate
256-435-2800
Frequently Asked Questions
What is the main goal of Acclinate's new initiative?
The initiative aims to mobilize clinical trial participants from Hispanic and Indigenous communities within 30 days, enhancing diversity in trials.
Why is diverse representation in clinical trials important?
Diverse representation ensures that treatments are safe and effective for all populations, not just the majority group, improving overall health outcomes.
How does the e-DICT™ platform work?
The e-DICT™ platform analyzes engagement data from various community channels to provide insights into participant willingness and sentiment.
Who leads Acclinate's strategic partnerships?
Meagan Holland serves as Acclinate's Director of Strategic Partnerships, focusing on building relationships with community organizations.
What sets Acclinate apart in the clinical research field?
Acclinate's unique blend of community engagement and technology enables it to reduce recruitment times and build trust with underrepresented populations effectively.
